Novo Nordisk and Eli Lilly are facing scores of personal injury claims for allegedly failing to warn patients about side ...

Courts have long deferred to CMS’s decisions on implementation of laws that govern Medicare. The overturning of the Chevron ...

HERSHEY, PA. — GLP-1 weight-loss drugs are having a “mild impact” on The Hershey Co.’s business, president and chief executive officer Michele Buck told analysts in a conference call on fiscal 2024 ...

HERSHEY, PA. — GLP-1 weight-loss drugs are having a “mild impact” on The Hershey Co.’s business, president and chief ...

Research, Clinical, and Policy Implications Discontinuation is a common issue for many chronic therapies, but it’s ...

Weight loss can be a challenge, even for those who eat healthily and exercise regularly. But injectable type 2 diabetes ...

Novo Nordisk (NYSE:NVO) (CSE:NOVOb) reported strong growth for the first nine months of 2024, with sales jumping by 23% in Danish kroner and 24% at constant exchange rates, reaching DKK 204.7 billion.

Most Americans are already familiar with semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist that Novo Nordisk markets as Ozempic and Rybelsus for diabetes ... investors who buy this stock ...

Obesity could be halved by the end of the decade if there was better access to weight-loss drugs like Ozempic and junk food ...

Milk prices have soared too as have wages, interest rates, fuel and transport — all price inputs for butter. Butter imports from Belarus are not sufficient so Russia is expecting a big shipment ...